Cavicchi M, Beau P, Crenn P, Degott C, Messing B
Hôpital Lariboisière-St. Lazare, Paris, France.
Ann Intern Med. 2000 Apr 4;132(7):525-32. doi: 10.7326/0003-4819-132-7-200004040-00003.
Liver cholestasis can be a life-threatening complication during home parenteral nutrition and may lead to combined liver-intestinal transplantation.
To assess the prevalence of home parenteral nutrition-related liver disease and its contributing factors in patients with permanent intestinal failure.
Prospective cohort study.
Two approved home parenteral nutrition centers.
90 patients with permanent intestinal failure who were receiving home parenteral nutrition were enrolled from 1985 to 1996.
Clinical, biological, endoscopic, and ultrasonographic follow-up. Histologic examination of the liver was done in 57 patients (112 liver biopsies).
The Kaplan-Meier method was used to determine the actuarial occurrence of chronic cholestasis and complicated home parenteral nutrition-related liver disease (bilirubin level > or =60 micromol/L [3.5 mg/dL], factor V level < or =50%, portal hypertension, encephalopathy, ascites, gastrointestinal bleeding, or histologically proven extensive fibrosis or cirrhosis). Contributing factors were assessed by using univariate and multivariate (Cox model) analysis.
58 patients (65%) developed chronic cholestasis after a median of 6 months (range, 3 to 132 months), and 37 (41.5%) developed complicated home parenteral nutrition-related liver disease after a median of 17 months (range, 2 to 155 months). Of these patients, 17 showed extensive fibrosis after 26 months (range, 2 to 148 months) and 5 had cirrhosis after 37 months (range, 26 to 77 months). The prevalence of complicated home parenteral nutrition-related liver disease was 26%+/-9% at 2 years and 50%+/-13% at 6 years. Six patients died of liver disease (22% of all deaths). In multivariate analysis, chronic cholestasis was significantly associated with a parenteral nutrition-independent risk for liver disease, a bowel remnant shorter than 50 cm in length, and a parenteral lipid intake of 1 g/kg of body weight per day or more (omega-6-rich long-chain triglycerides), whereas complicated home parenteral nutrition-related liver disease was significantly associated with chronic cholestasis and lipid parenteral intake of 1 g/kg per day or more.
The prevalence of complicated home parenteral nutrition-related liver disease increased with longer duration of parenteral nutrition. This condition was one of the main causes of death in patients with permanent intestinal failure. Parenteral intake of omega-6-rich long-chain triglycerides lipid emulsion consisting of less than 1 g/kg per day is recommended in these patients.
肝内胆汁淤积可能是家庭肠外营养期间一种危及生命的并发症,并且可能导致肝肠联合移植。
评估永久性肠衰竭患者中家庭肠外营养相关肝病的患病率及其影响因素。
前瞻性队列研究。
两个获批的家庭肠外营养中心。
1985年至1996年纳入90例接受家庭肠外营养的永久性肠衰竭患者。
临床、生物学、内镜及超声随访。57例患者(112次肝活检)进行了肝脏组织学检查。
采用Kaplan-Meier法确定慢性胆汁淤积和复杂的家庭肠外营养相关肝病(胆红素水平≥60 μmol/L [3.5 mg/dL]、凝血因子V水平≤50%、门静脉高压、肝性脑病、腹水、胃肠道出血或组织学证实的广泛纤维化或肝硬化)的实际发生率。通过单因素和多因素(Cox模型)分析评估影响因素。
58例患者(65%)在中位时间6个月(范围3至132个月)后发生慢性胆汁淤积,37例患者(41.5%)在中位时间17个月(范围2至155个月)后发生复杂的家庭肠外营养相关肝病。在这些患者中,17例在26个月(范围2至148个月)后出现广泛纤维化,5例在37个月(范围26至77个月)后出现肝硬化。复杂的家庭肠外营养相关肝病的患病率在2年时为26%±9%,在6年时为50%±13%。6例患者死于肝病(占所有死亡患者的22%)。在多因素分析中,慢性胆汁淤积与不依赖肠外营养的肝病风险、长度短于50 cm的肠残余以及每天每千克体重1 g或更多的肠外脂肪摄入量(富含ω-6的长链甘油三酯)显著相关,而复杂的家庭肠外营养相关肝病与慢性胆汁淤积和每天每千克体重1 g或更多的肠外脂肪摄入量显著相关。
复杂的家庭肠外营养相关肝病的患病率随着肠外营养持续时间的延长而增加。这种情况是永久性肠衰竭患者的主要死亡原因之一。建议这些患者肠外摄入每天每千克体重少于1 g的富含ω-6的长链甘油三酯脂肪乳剂。